Renal cell carcinoma in focus: Improving the therapeutic index of IL-2

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 12, 2010, Pages 862-864

  Mcdermott, David F ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; VASCULOTROPIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; RECOMBINANT PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HUMAN; KIDNEY CARCINOMA; METASTASIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT DURATION; CLINICAL TRIAL (TOPIC); KIDNEY TUMOR; METHODOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; RECOMBINANT PROTEINS; RESEARCH DESIGN;

EID: 78651256386     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res. 2005; 11:3714-3721.
2. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802-811.
3. Leibovich BC, Han K, Bui MHT, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;98:2566-2575.
4. McDermott DF, Ghebremichael MS, Signoretti S, et al.The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol (ASCO Meeting Abstracts). 2010;28(15s). Abstract 4514.
5. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of highdose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
6. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005;28:488-495.
7. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.